Cargando…

Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach

[Image: see text] Aim/Hypothesis: The complexity and heterogeneity of multiple pathological features make Alzheimer’s disease (AD) a major culprit to global health. Drug repurposing is an inexpensive and reliable approach to redirect the existing drugs for new indications. The current study aims to...

Descripción completa

Detalles Bibliográficos
Autores principales: Advani, Dia, Kumar, Pravir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173619/
https://www.ncbi.nlm.nih.gov/pubmed/34095679
http://dx.doi.org/10.1021/acsomega.1c01526
_version_ 1783702759927709696
author Advani, Dia
Kumar, Pravir
author_facet Advani, Dia
Kumar, Pravir
author_sort Advani, Dia
collection PubMed
description [Image: see text] Aim/Hypothesis: The complexity and heterogeneity of multiple pathological features make Alzheimer’s disease (AD) a major culprit to global health. Drug repurposing is an inexpensive and reliable approach to redirect the existing drugs for new indications. The current study aims to study the possibility of repurposing approved anticancer drugs for AD treatment. We proposed an in silico pipeline based on “omics” data mining that combines genomics, transcriptomics, and metabolomics studies. We aimed to validate the neuroprotective properties of repurposed drugs and to identify the possible mechanism of action of the proposed drugs in AD. Results: We generated a list of AD-related genes and then searched DrugBank database and Therapeutic Target Database to find anticancer drugs related to potential AD targets. Specifically, we researched the available approved anticancer drugs and excluded the information of investigational and experimental drugs. We developed a computational pipeline to prioritize the anticancer drugs having a close association with AD targets. From data mining, we generated a list of 2914 AD-related genes and obtained 49 potential druggable targets by functional enrichment analysis. The protein–protein interaction (PPI) studies for these genes revealed 641 interactions. We found that 15 AD risk/direct PPI genes were associated with 30 approved oncology drugs. The computational validation of candidate drug–target interactions, structural and functional analysis, investigation of related molecular mechanisms, and literature-based analysis resulted in four repurposing candidates, of which three drugs were epidermal growth factor receptor (EGFR) inhibitors. Conclusion: Our computational drug repurposing approach proposed EGFR inhibitors as potential repurposing drugs for AD. Consequently, our proposed framework could be used for drug repurposing for different indications in an economical and efficient way.
format Online
Article
Text
id pubmed-8173619
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-81736192021-06-04 Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach Advani, Dia Kumar, Pravir ACS Omega [Image: see text] Aim/Hypothesis: The complexity and heterogeneity of multiple pathological features make Alzheimer’s disease (AD) a major culprit to global health. Drug repurposing is an inexpensive and reliable approach to redirect the existing drugs for new indications. The current study aims to study the possibility of repurposing approved anticancer drugs for AD treatment. We proposed an in silico pipeline based on “omics” data mining that combines genomics, transcriptomics, and metabolomics studies. We aimed to validate the neuroprotective properties of repurposed drugs and to identify the possible mechanism of action of the proposed drugs in AD. Results: We generated a list of AD-related genes and then searched DrugBank database and Therapeutic Target Database to find anticancer drugs related to potential AD targets. Specifically, we researched the available approved anticancer drugs and excluded the information of investigational and experimental drugs. We developed a computational pipeline to prioritize the anticancer drugs having a close association with AD targets. From data mining, we generated a list of 2914 AD-related genes and obtained 49 potential druggable targets by functional enrichment analysis. The protein–protein interaction (PPI) studies for these genes revealed 641 interactions. We found that 15 AD risk/direct PPI genes were associated with 30 approved oncology drugs. The computational validation of candidate drug–target interactions, structural and functional analysis, investigation of related molecular mechanisms, and literature-based analysis resulted in four repurposing candidates, of which three drugs were epidermal growth factor receptor (EGFR) inhibitors. Conclusion: Our computational drug repurposing approach proposed EGFR inhibitors as potential repurposing drugs for AD. Consequently, our proposed framework could be used for drug repurposing for different indications in an economical and efficient way. American Chemical Society 2021-05-19 /pmc/articles/PMC8173619/ /pubmed/34095679 http://dx.doi.org/10.1021/acsomega.1c01526 Text en © 2021 The Authors. Published by American Chemical Society Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Advani, Dia
Kumar, Pravir
Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
title Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
title_full Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
title_fullStr Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
title_full_unstemmed Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
title_short Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer’s Disease: Using the Multiomics Approach
title_sort therapeutic targeting of repurposed anticancer drugs in alzheimer’s disease: using the multiomics approach
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173619/
https://www.ncbi.nlm.nih.gov/pubmed/34095679
http://dx.doi.org/10.1021/acsomega.1c01526
work_keys_str_mv AT advanidia therapeutictargetingofrepurposedanticancerdrugsinalzheimersdiseaseusingthemultiomicsapproach
AT kumarpravir therapeutictargetingofrepurposedanticancerdrugsinalzheimersdiseaseusingthemultiomicsapproach